Skip to main content
TipRanks
Go Ultimate75% OFF

Vext Science (VEXT) AI Stock Analysis

20 Followers
TSE:VEXT

Vext Science

(CNQX:VEXT)

Select Model
Rating:45Neutral
Price Target:CAD 0.17â–¼(-7.57% Downside)
Action:reiterated
Date:11/05/26

Vext Science's overall score of 45 is heavily dragged down by severe profitability challenges, capital erosion, and strong bearish technical trends. The company's deep unprofitability is reflected in its negative P/E ratio and steeply declining margins. However, the recent earnings call provides a silver lining: management's strategic focus on the Ohio market, margin expansions, and narrowing net losses suggest potential for a future turnaround, though significant near-term execution risks remain.

Positive Factors
Margin and EBITDA improvementThe sharp improvement in gross margin and adjusted EBITDA indicates better operating execution and stronger contribution from the current business mix. If sustained, these gains can improve earnings quality, support internal investment, and strengthen the company’s ability to manage debt over the next several quarters.
Negative Factors
Revenue pressure and Arizona weaknessTop-line contraction remains a fundamental challenge because revenue is declining even as management works to improve margins. Reduced Arizona wholesale activity and weaker demand can limit operating leverage, make fixed costs harder to absorb, and place greater execution demands on Ohio expansion.

Vext Science (VEXT) vs. iShares MSCI Canada ETF (EWC)

-30%-20%-10%0%10%20%30%40%TSE:VEXT-26.00%EWC+13.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 31.23M
Dividend Yield
―
Average Volume (3M)
62.67K
Price to Earnings (P/E)
-1.5
Beta (1Y)
0.45
Revenue Growth
9.88%
EPS Growth
0.18%
Country
Canada
Employees
173
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Vext Science Business Overview & Revenue Model

Company Description

Vext Science, Inc. operates as a comprehensive enterprise within the United States' cannabis sector, encompassing agricultural technology, various services, and property management. The company is actively involved in cultivating, extracting, manufac...

Vext Science Earnings Call Summary

Earnings Call Date:Aug 20, 2026(Q2-2026)|% Change Since:-37.29%|Next Earnings Date:Jun 01, 2020
Earnings Call SentimentPositive

The call emphasized meaningful operational and margin improvements driven by Ohio execution and higher cultivation yields, alongside successful financing and balance sheet progress. These positives were balanced against a lower top line (driven by a planned Arizona cultivation wind-down), ongoing market weakness in Arizona, a significant uncertain tax liability, and modest reported operating cash flow due to deliberate inventory and payable timing. Management communicated a clear strategy to redeploy capital from Arizona to Ohio and to pay down debt, and they reported concrete near-term actions and improving trends.

Positive Updates

Improved Profitability and Margins
Gross profit rose to $6.7M from $4.9M a year ago and gross margin expanded to 55% (vs 36% prior year). Even before fair-value adjustments, margin improved to ~44% from ~39% year-over-year.

Negative Updates

Revenue Decline
Total revenue was $12.1M, down ~10% year-over-year; top-line decline driven primarily by a planned reduction in Arizona wholesale activity (wholesale revenue declined from $2.6M to $1.4M).

Company Guidance

Management guided to improved H2 performance as Arizona’s repositioning to a capital‑light retail/third‑party sourcing model completes, Ohio inventory converts to cash, Fairfield and the broader Ohio footprint scale, and capital is directed to strengthening the balance sheet, paying down debt, and funding Ohio growth; Q2 metrics cited as context include revenue of $12.1M (≈‑10% YoY, flat QoQ) with wholesale revenue down to $1.4M from $2.6M, gross profit $6.7M (vs $4.9M a year ago) and gross margin 55% (36% YoY; 44% before fair‑value adj.), adjusted EBITDA $3.4M (+22% QoQ from a corrected Q1 $2.8M) with a 28% adjusted EBITDA margin (vs 23%), net loss narrowed to $0.3M (vs $1.5M), cash from operations $1.2M (~10% cash‑flow margin) despite a deliberate $2M Ohio inventory build (expected to convert through H2; Ohio wholesale set a preliminary monthly record in July), cultivation yields now >100 g/plant (up ~68% over 2.5 years), Eloy property reclassified held‑for‑sale at $7.8M with proceeds earmarked to pay secured debt, cash ~$4.5M, net working capital improved from ‑$11.7M to ≈‑$0.9M (would be positive excluding an $11.7M uncertain tax position up from $8.1M), WPCU financing gross proceeds ≈$17M (used to refinance ~$10.5M WPCU debt, acquire Jackson, OH for $6M and fund expansion), and the East West Bank note maturity extended to Jan 2028.

Vext Science Financial Statement Overview

Summary

Vext Science presents a challenging financial profile. Despite robust revenue growth, gross margins have plummeted to 6.8% in the TTM period, leading to deeply negative net profit margins and steady capital erosion. While the company maintains positive operating cash flow, negative free cash flow and a worsening debt-to-equity ratio pose structural risks.

Income Statement

30Negative

Balance Sheet

40Negative

Cash Flow

50Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue52.74M52.27M36.00M34.81M35.41M37.24M
Gross Profit3.50M2.32M8.98M12.04M23.10M18.69M
EBITDA1.92M6.80M-2.02M16.77M15.29M12.82M
Net Income-11.60M-18.31M-22.44M4.40M10.92M4.99M
Balance Sheet
Total Assets118.95M120.31M136.97M149.56M120.52M83.70M
Cash, Cash Equivalents and Short-Term Investments5.58M5.07M4.62M8.72M5.93M6.47M
Total Debt38.61M34.97M39.52M38.60M38.15M14.10M
Total Liabilities69.97M65.04M61.23M54.58M48.60M24.31M
Stockholders Equity48.98M55.27M75.74M94.98M71.92M59.39M
Cash Flow
Free Cash Flow-1.18M8.29M1.82M1.69M-2.94M-7.10M
Operating Cash Flow8.37M11.92M3.29M4.42M5.92M11.68M
Investing Cash Flow-9.47M-5.76M-5.44M-4.82M-30.31M-27.10M
Financing Cash Flow3.07M-5.69M-1.95M3.19M23.86M20.14M

Vext Science Technical Analysis

Technical Analysis SentimentNegative
Last Price0.18

Price Trends

50DMA0.24Negative
100DMA0.25Negative
200DMA0.26Negative

Market Momentum

MACD-0.02Positive
RSI37.69Neutral
STOCH6.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.24, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.69 is Neutral, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.

Vext Science Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:VEXT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS60NeutralCAD 23.49M-8.46-7.66%―-9.31%66.84%
TSE:AVCNTSE:AVCN58NeutralCAD 11.42M-3.86-65.40%―-3.32%-34.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:VEXTTSE:VEXT45NeutralCAD 45.83M-1.54-31.34%―9.88%0.18%
TSE:LEEFTSE:LEEF43NeutralCAD 61.11M-1.57206.83%―――
TSE:CWEBTSE:CWEB42NeutralCAD 66.47M-0.89-139.31%―-9.90%-35.35%
TSE:PLTHTSE:PLTH39UnderperformCAD 33.53M-0.95-59.17%―-15.64%71.65%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%800%TSE:VEXTTSE:LEEFTSE:CWEBTSE:LABSTSE:PLTHTSE:AVCNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:VEXT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:VEXTVext Science0.18-0.07-26.00%
TSE:LEEFLeef Brands Inc0.20-0.03-14.89%
TSE:CWEBCharlotte's Web Holdings (OTC)0.240.1181.48%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-15.38%
TSE:PLTHPlanet 13 Holdings, Inc.0.10-0.16-61.54%
TSE:AVCNAvicanna Inc0.09-0.15-64.58%

Vext Science Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance

Vext Reports Record Revenue and Stronger Operating Cash Flow

Positive
Nov 3, 2026

Vext Science is a U.S.-based specialty retailer of regulated cannabis products, including flower and packaged goods, operating in Ohio and Arizona. Third-quarter revenue reached a record $14.9 million, up 23% sequentially and 18% year over year, whil...

Business Operations and Strategy

Vext Science Reaches Ohio Dispensary Cap With Amelia License

Positive
Oct 29, 2026

Vext Science has secured a provisional dual-use license for its eighth Ohio dispensary in Amelia, reaching the maximum number of stores allowed for a single operator in the state. The new location, paired with the recently opened Fairfield dispensary...

Business Operations and StrategyFinancial Disclosures

Vext Science Sets November 3 Date for Q3 2026 Results

Neutral
Oct 29, 2026

Vext Science, Inc., a U.S.-based specialty cannabis retailer operating in Ohio and Arizona, runs a largely vertically integrated model by owning its dispensaries, most underlying real estate, and supplying shelves from its own cultivation and manufac...

Business Operations and StrategyRegulatory Filings and Compliance

Vext Science Regains Full Sales Clearance for Vapen Products in Ohio

Positive
Oct 15, 2026

Vext Science, Inc., a specialty cannabis retailer with vertically integrated operations in Ohio and Arizona, has built a model around owning its dispensaries and much of its real estate while supplying stores from both internal production and select...

Business Operations and StrategyPrivate Placements and Financing

Vext Reopens Ohio Dispensary and Eases 2026 Debt Maturity Burden

Positive
Sep 17, 2026

Vext Science has reopened its Herbal Wellness Center dispensary in Jackson, Ohio after receiving authorization from the Ohio Division of Cannabis Control, restoring service to patients and customers in the area. The company emphasized its commitment...

Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance

Vext Science Shuts Jackson, Ohio Dispensary Amid Health-Event Probe

Negative
Sep 4, 2026

Vext Science has voluntarily closed its Herbal Wellness Center dispensary in Jackson, Ohio at the request of the Ohio Division of Cannabis Control, which is investigating two serious adverse health events possibly involving products purchased at that...

Business Operations and StrategyFinancial Disclosures

Vext Science Boosts Q2 Profitability as Ohio Growth Offsets Arizona Exit

Positive
Aug 20, 2026

Vext Science reported second-quarter 2026 revenue of $12.1 million, in line with the prior quarter, as growth in Ohio retail offset the planned wind-down of Arizona cultivation and wholesale operations. Adjusted EBITDA rose 22% sequentially to $3.4 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026